The Filing Desk

Kymera Therapeutics

KYMR · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

KYMR · Last close · November 13, 2026
$127.57
Value Kymera Therapeutics yourself

Kymera Therapeutics' revenue fell 16.7% to $39 million in fiscal 2025. Its operating margin was −891.1%, down from −555.8% a year earlier. Free cash flow was −$234 million. The diluted share count rose 12.6%.

KYMERA THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-073395 Updated
Revenue
$39M
16.7%
Operating margin
−891.1%
335.2 pts
Net income
−$311M
 
Free cash flow
−$234M
 
Return on equity
−25.8%
10.6 pts
Market cap
$12.8B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Kymera Therapeutics does

Kymera Therapeutics is a clinical-stage biopharmaceutical company, which means it tests its medicines in people and has none approved for sale. It works on targeted protein degradation, an approach in which a small-molecule medicine uses the body's natural cellular recycling system to remove a protein that drives disease, instead of just blocking it.

Its work is mainly aimed at immune and inflammatory diseases. Kymera wants to offer a daily pill that works like the injected biologic drugs now used for many of these patients. Its publicly disclosed programs target three proteins: STAT6, IRF5 and IRAK4. Its lead medicine in the STAT6 program, KT-621, is in Phase 2b trials in adults and adolescents with moderate to severe atopic dermatitis (a skin condition) and in adults with moderate to severe asthma. KT-579, an oral IRF5 degrader, has started a Phase 1 trial.

Kymera says it expects to start clinical testing of at least one new molecule each year, and it hopes to become a fully integrated drug company. It was formed in 2015.

Its biggest risks, as it describes them

  • It is a clinical-stage company, so it is hard to judge its business to date or its future.
  • It has lost money since it began and expects more losses for the foreseeable future.
  • It will need substantial additional money, and raising it may dilute its shareholders.
  • Its drug candidates may fail in clinical trials or fail to win regulatory approval.
  • Targeted protein degradation is a new kind of medicine, so its development path is hard to predict.
From Kymera Therapeutics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Kymera Therapeutics lost money in fiscal 2025: a net loss of $311 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments442407375489848
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−636.3x−900.9x−1,021.8x−1,270.1x−1,119.9x
Current ratio4.9x5.9x4.7x7.5x10.5x
Quick ratio4.9x5.9x4.7x7.5x10.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Kymera Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $172.5 million of Kymera Therapeutics shares on the open market, and 11 insiders sold $461.2 million, $263.0 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 4, 2026Brian AdamsChief Legal OfficerSold6,371$116.83$744,297Form 4
Jul 7, 2026Nello MainolfiChief Executive Officer, DirectorSold plan50,000$119.00$6.0 millionForm 4
Jul 1, 2026Nello MainolfiChief Executive Officer, DirectorSold plan80,000$115.30$9.2 millionForm 4
Jul 1, 2026Noah GoodmanChief Business OfficerSold plan3,389$114.29$387,329Form 4
Jun 30, 2026Bruce N. JacobsChief Financial OfficerSold plan77,109$114.97$8.9 millionForm 4
Jun 29, 2026Bruce BoothDirectorSold plan45,367$107.06$4.9 millionForm 4
Jun 29, 2026Bruce BoothDirectorSold plan31,283$109.48$3.4 millionForm 4
Jun 26, 2026Biotechnology Value Fund II LpDirectorSold1,630,658$106.50$173.7 millionForm 4
Jun 26, 2026Bruce BoothDirectorSold plan467,878$110.29$51.6 millionForm 4
Jun 25, 2026Bruce BoothDirectorSold plan285,684$121.86$34.8 millionForm 4
Jun 25, 2026Bruce BoothDirectorSold plan262,637$115.39$30.3 millionForm 4
Jun 25, 2026Noah GoodmanChief Business OfficerSold plan5,000$114.00$570,000Form 4
The latest 12 of 58 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−106.9%−480.6%−614.3%
Altman Z''1.004.829.79
Accruals ratio−7.5%−3.8%−5.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Kymera Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Kymera TherapeuticsFY25−16.7%−891.1%−597.6%———
Editas MedicineFY2525.4%−394.9%−409.3%——2Compare
Wave Life SciencesFY25−60.5%−504.1%−440.5%———Compare
Protagonist TherapeuticsFY25−89.4%−343.6%121.9%———Compare
SepternaFY254,174.5%−148.6%238.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue3347347794739
Revenue growth—1,060.0%114.0%−35.7%67.8%−40.1%−16.7%
Gross profit———0000
Research and development3762137164189240317
Operating income−42−46−100−161−166−262−349
Net income−41−46−100−155−147−224−311
Diluted EPS (US$)−24.28−3.15−2.09−2.87−2.52−2.98−3.69
Diluted shares (millions)2174854587584
Cash flow
Cash from operations1888−129−153−103−194−233
Capital expenditure092334131
Free cash flow1779−131−156−137−207−234
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation152536435560
Balance sheet at fiscal year end
Cash and short-term investments92296442407375489848
Debt incl. finance leases———————
Total assets1174876066035769781,743
Total liabilities82203146113181142163
Shareholders' equity−742844604903958361,580
Margins and ratios
Gross margin———0.0%0.0%0.0%0.0%
Operating margin−1,438.5%−136.1%−138.0%−344.4%−210.6%−555.8%−891.1%
Net margin−1,405.8%−134.0%−137.6%−330.6%−187.0%−475.6%−794.0%
Free cash flow margin592.1%232.2%−179.2%−333.0%−174.7%−440.5%−597.6%
Rule of 40 (growth + FCF margin)—1,292.2%−65.2%−368.7%−106.9%−480.6%−614.3%
Return on capital———————
Return on equity—−43.5%−27.0%−32.6%−33.2%−36.4%−25.8%
Return on assets—−15.1%−18.3%−25.6%−24.9%−28.8%−22.9%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Kymera Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Kymera Therapeutics.